An inconvenient hurdle in the practice of nanomedicine is the protein corona, a spontaneous
collection of biomolecular species by nanoparticles in living systems. The protein corona is …

Liposomes, the most widely studied nano-drug carriers in drug delivery, are sphere-shaped
vesicles consisting of one or more phospholipid bilayers. Compared with traditional drug …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

For systemically delivered nanoparticles to reach target tissues, they must first circulate long
enough to reach the target and extravasate there. A challenge is that the particles end up …

The drugs used for cancer treatment have many drawbacks, as they damage both tumor and
healthy cells and, in addition, they tend to be poorly soluble drugs. Their transport in …

Nanomaterials are promising carriers to improve the bioavailability and therapeutic
efficiency of drugs by providing preferential drug accumulation at their sites of action, but …

The therapeutic efficacy and adverse impacts of nanoparticles (NPs) are strongly dependent
on their systemic circulation time. The corona proteins adsorbed on the NPs determine their …

Poly (ethylene glycol)(PEG) is the gold standard used to reduce unspecific protein
adsorption and prolong nanocarrier circulation time. However, this stealth effect could be …

With excellent physicochemical properties, inorganic nanomaterials (INMs) have exhibited a
series of attractive applications in biomedical fields. Biological barriers prevent successful …

Lipid nanoparticles (LNPs) play a crucial role in addressing genetic disorders, and cancer,
and combating pandemics such as COVID-19 and its variants. Yet, the ability of LNPs to …